

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) for 1.97(c))					Docket No. 2488.017	
In Re Application Of: GRONER, Yoram						
Application No. 10/540,402	Filing Date 06/23/05	Examiner Unknown	Customer No. 23405	Group Art Unit 1614	Confirmation No. 8368	
Title: METHODS FOR EVALUATING GENETIC SUSCEPTIBILITY AND THERAPY FOR CHRONIC INFLAMMATORY DISEASES						
<p>Address to:</p> <p>Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p>37 CFR 1.97(b)</p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;">37 CFR 1.97(c)</p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="margin-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center;">OR</p> <p style="margin-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>						

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
2488.017

In Re Application of: GRONER, Yoram

SEP 28 2005

Application No. 10/540,402	Filing Date 06/23/05	Examiner Unknown	Customer No. 23405	Group Art Unit 1614	Confirmation No. 8368
-------------------------------	-------------------------	---------------------	-----------------------	------------------------	--------------------------

Title: **METHODS FOR EVALUATING GENETIC SUSCEPTIBILITY AND THERAPY FOR CHRONIC INFLAMMATORY DISEASES**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

Sept. 26, 2005


(Date)

Signature of Person Mailing Correspondence

Jeff Rothenberg

Typed or Printed Name of Person Mailing Certificate


*This certificate may only be used if paying by deposit account.


Signature

Dated: Sept. 26, 2005


Jeff Rothenberg, Reg. No. 26,429
Heslin Rothenberg Farley & Mesiti P.C.
5 Columbia Circle
Albany, NY 12203
Tel: 518-452-5600
Fax: 518-452-5579
E-mail: jr@hrfmlaw.com

cc:

 <p>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>		Docket Number (Optional) 2488.017		Application Number 10/540,402	
		Applicant(s) GRONER, Yoram			
		Filing Date 06/23/05		Group Art Unit 1614	
<p>*EXAMINER INITIAL OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</p>					
AA		Akbari, O., Stock, P., DeKruyff, R.H. and Umetsu, D.T. (2003) Mucosal tolerance and immunity: regulating the development of allergic disease and asthma. <i>Int Arch Allergy Immunol</i> , 130, 108-118.			
AB		Austyn, J.M., Steinman, R.M., Weinstein, D.E., Granelli-Piperno, A. and Palladino, M.A. (1983) Dendritic cells initiate a two-stage mechanism for T lymphocyte proliferation. <i>J Exp Med</i> , 157, 1101-1115.			
AC		Banchereau, J. and Steinman, R.M. (1998) Dendritic cells and the control of immunity. <i>Nature</i> , 392, 245-252.			
AD		Bangsow, C., Rubins, N., Glusman, G., Bernstein, Y., Negraru, V., Goldenberg, D., Lotem, J., Ben-Asher, E., Lancet, D., Levanon, D. and Groner, Y. (2001) The RUNX3 gene—sequence, structure and regulated expression. <i>Gene</i> , 279, 221-232.			
AE		Borkowski, T.A., Letterio, J.J., Far, A.G. and Udey, M.C. (1996) A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. <i>J Exp Med</i> . 184, 2417-2422.			
AF		Holt, P.G. (2000) Antigen presentation in the lung. <i>Am J Respir Crit Care Med</i> . 162, S151-156.			
AG		Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S. and Steinman, R.M. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. <i>J Exp Med</i> , 176, 1693-1702.			
AH		Ito, Y. and Miyazono, K. (2003) RUNX transcription factors as key targets of TGF-beta superfamily signaling. <i>Curr Opin Genet Dev</i> , 13, 43-47.			
AI		Julia, V., Hessel, E.M., Malherbe, L., Glaichenhaus, N., O'Garra, A. and Coffman, R.L. (2002) A restricted subset of dendritic cells captures airborne antigens and remains able to activate specific T cells long after antigen exposure. <i>Immunity</i> , 16, 271-283.			
AJ		Jung, S., Aliberti, J., Graemmel, P., Sunshine, J.J., Kreutzberg, G.W., Sher, A. and Littman, D.R. (2000) Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. <i>Mol Cell Biol</i> , 20, 4106-4114.			
AK		Levanon, D., Bettoun, D., Harris-Cerruti, C., Woolf, E., Negraru, V., Eilam, R., Bernstein, Y., Goldenberg, D., Xiao, C., Fliegau, M., Kremer, E., Otto, F., Brenner, O., Lev-Tov, A. and Groner, Y. (2002) The Runx3 transcription factor regulates development and survival of TrkC forsal root ganglia neurons. <i>Embo J.</i> , 21, 3454-3463.			
AL		Levanon, D., Brenner, O., Negraru, V., Bettoun, D., Woolf, E., Eilam, R., Lotem, J., Gat, U., Otto, F., Speck, N. and Groner, Y. (2001a) Spatil and temporal expression pattern of Runx3 (Aml2) and Runx1 (Aml1) indicates non-redundant functions during mouse embryogenesis. <i>Mech Dev</i> , 109, 413-417.			
EXAMINER			DATE CONSIDERED		
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					

**SUPPLEMENTAL
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



Docket Number (Optional) 2488.017	Application Number 10/540,402
Applicant(s) GRONER, Yoram	
Filing Date 06/23/05	Group Art Unit 1614

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AM	Levanon, D., Goldstein, R.E., Bernstein, Y., Tang, H., Goldenberg, D., Stifani, S., Paroush, Z. and Groner, Y. (1998) Transcriptional repression by AML1 and LEF-1 is mediated by the ELE/Groucho corepressors. <i>Proc. Natl. Acad. Sci. USA</i> , 1995, 11590-11595.
AN	Levanon, D., Brenner, O., Otto, F. and Groner, Y. (2003a) Runx3 knockouts and stomach cancer. <i>EMBO Rep</i> , 4, 560-564.
AO	Li, Q.L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K., Chi, X.Z., Lee, K.Y., Nomura, S., Lee, C.W., Han, S.B., Kim, H.M., Kim, W.J., Yamamoto, H., Yamashita, N., Yano, T., Ikeda, T., Itohara, S., Inazawa, J., Abe, T., Hagiwara, A., Yamagishi, H., Ooe, A., Kaneda, A., Sugimura, T., Ushijima, T., Bae, S.C. and Ito, Y. (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. <i>Cell</i> , 109, 113-124.
AP	Nathan, C. (2002) Points of control in inflammation. <i>Nature</i> , 420, 846-852.
AQ	Puig-Kroger, A., Sanchez-Elsner, T., Ruiz, N., Andreu, E.J., Prosper, F., Jensen, U.B., Gil, J., Erickson, P., Drabkin, H., Groner, Y. and Corbi, A.L. (2003) RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements. <i>Blood</i> .
AR	Shi, M.J. and Stavnezer, J. (1998) CBF alpha3 (AML2) is induced by TGF-beta1 to bind and activate the mouse germline Ig alpha promoter. <i>J Immunol</i> , 161, 6751-6760.
AS	Topiksi, I., Harmelin, A., Flavell, R.A., Levo, Y. and Shachar, I. (2002) Preferential Th1 immune response in invariant chain-deficient mice. <i>J Immunol</i> , 168, 1610-1617.
AT	Vermaelen, K.Y., Carro-Muino, I., Lambrecht, B.N. and Pauwels, R.A. (2001) Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. <i>J Exp Med</i> , 193, 51-60.
AU	Yamaguchi, Y., Tsumura, H., Miwa, M. and Inaba, K. (1997) Contrasting effect of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. <i>Stem Cells</i> , 15, 144-153.
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.